Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by Gamestorm7on Aug 21, 2018 1:45pm
209 Views
Post# 28494113

My Opinion

My OpinionIf you look at the timeline of information and try and connect the dots, the story is being told before our eyes. Mr. Rae buys over 1M shares in May when (I'm assuming) the first results of Phase 1 clinical trials of Oral Amp B prove positive and show no toxicity. The CEO feels that they have developed a breakthrough and acts accordingly. The company goes on to release a corporate update and announce final recruitment of Phase 1 trial in June. The company provides further press releases indicating that Phase 1 is a success and reiterates that they believe the results put them in a clear leadership position in the race to develop an Oral version of Amp B. The company's float trades over 3 times in volume the coming months and reaches a high of $0.275 before a sell off on positive news indicating that the company is securing intellectual property rights before releasing the "important and material" pharmacokinetic data from Phase I trials. Retail sells as it wasn't the news of a partnership or JV etc which was being pumped on forums such as this one. A lot of people had made money and sold to chase SIC. The stock price has settled at 0.09-0.12 since and there has been steady accumulation. Nothing has changed for ICO. I am assuming that the "material and important" pharmacokinetic data that the company was greatly anticipating makes for a good bargaining chip when doing dealings with a potential partner. Also, having the intellectual property patent on your recent formulation breakthrough helps as well. In my opinion, any news of advancement into Phase II trials and a solid financing is good; however, I expect a partnership or JV deal to be announced as ICO has the potential to take over a drug market in the $Billions. I would assume that is attractive to Big Pharma companies. My opinions only. GLTA
<< Previous
Bullboard Posts
Next >>